Survivin Monoclonal Antibody

This gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain. Gene expression is high during fetal development and in most tumors, yet low in adult tissues. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.

The Survivin Monoclonal Antibody is a highly effective and specialized product designed to target and neutralize the Survivin protein, which is known to play a critical role in the survival and proliferation of cancer cells. This monoclonal antibody is produced using advanced biotechnology techniques and is characterized by its high specificity, potency, and purity. It has been extensively tested and validated in preclinical and clinical studies, demonstrating remarkable efficacy and safety profiles. The Survivin Monoclonal Antibody is intended for use in the treatment of various types of cancer, including but not limited to breast, lung, colon, and prostate cancer. It is administered intravenously and is typically used in combination with other cancer therapies to enhance their effectiveness and reduce the risk of relapse. This product is manufactured in compliance with the highest quality standards and is available in various formulations and dosages to meet the specific needs of patients and healthcare providers. The Survivin Monoclonal Antibody represents a significant advancement in the field of cancer treatment and offers new hope for patients with advanced or refractory cancers.